QualityStocks.net News – Novavax Inc. (NVAX) Announces New Proprietary Process to Battle SARS

At www.QualityStocks.Net you can sign up for Quality Stock's Daily Newsletter to find out what Small-Cap and Micro-Cap online Investment Newsletters are interested in, plus hear about the latest news from our clients as well as other publicly traded companies.

We would like to highlight Novavax Inc. (Nasdaq: NVAX). The company is a biopharmaceutical company focused on creating differentiated vaccines that leverage the Company’s virus-like particle (VLP) technology, as well as its Novasomes adjuvants. Its product targets include vaccines against the H5N1, H9N2 and other subtypes of avian influenza with pandemic potential and against human seasonal influenza, as well as other infectious diseases.

In the Company’s recent news,

Novavax Inc. announced it has launched a new proprietary process to develop a vaccine candidate to fight the viral respiratory illness, Severe Acute Respiratory Syndrome (SARS). To assist in its research efforts and preclinical developments of the SARS vaccine, the company received funding from the National Institutes of Health (NIH).

“Until now, it has been difficult to produce VLP vaccine candidates against SARS and other complex infectious disease targets because many of these biological structures do not assemble efficiently,” Dr. Gale Smith, Ph.D., vice president of Vaccine Development, stated in the press release. “Our new proprietary process uses select components of SARS and other structural proteins that combine with cell membranes to form distinctive SARS coronavirus nanoparticles, which are nearly identical to the human SARS virus but lack the genetic material needed to replicate and cause disease.”

Though Novavax does not have commercial rights to the product candidate, the NIH funding will help the company further its research and developments to fight SARS. According to the World Health Organization, health officials are concerned that SARS could become the first severe new disease of the 21st century with global epidemic, or pandemic, potential.

“This new approach to create VLPs will allow us to continue our work to develop a SARS vaccine candidate and expand the potential applications of our vaccine technology to a broad range of infectious diseases around the world,” Rahul Singhvi, president and CEO of Novavax stated in the press release.

About QualityStocks

QualityStocks.net, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks.net is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.